Quick Answer: Yes, the same cosmetic product may be sold in the EU and UK if it meets the requirements of each intended market. A shared formula does not automatically mean a shared label, responsible person or notification. Review the EU, Great Britain and Northern Ireland separately, then document which formulation, packaging and compliance records support each market release.
By mooyam_admin (MOOYAM editorial team). Last reviewed: 8 October 2026. Cover: AI-generated editorial illustration.
What does “the same product” actually mean?
For a beauty brand, one product can mean one formula, one packaging design, one commercial SKU or one technical evidence package. These are different decisions. Keeping the formula unchanged may simplify manufacturing, but it does not remove market-specific obligations. This guide focuses on a practical dual-market release decision rather than treating an EU launch as automatic permission to sell throughout the UK.
Start by identifying the territories where customers will receive the product. Great Britain means England, Scotland and Wales. Northern Ireland has a distinct cosmetics route. For a broader overview of the legal systems, see our EU vs UK cosmetic regulations comparison.
Which market routes must the brand check?
| Destination | Responsible-person route | Notification route |
|---|---|---|
| European Union | Responsible person established in the EU, under the EU cosmetics framework | Cosmetic Products Notification Portal (CPNP) |
| Great Britain | UK-established responsible person under the GB framework | Submit Cosmetic Product Notifications (SCPN) |
| Northern Ireland | Responsible person established in Northern Ireland or the EEA, under the applicable EU framework | CPNP; assess any specific movement arrangements separately |
The European Commission identifies Regulation (EC) No 1223/2009 as the principal EU cosmetics framework and explains responsible-person and safety-report obligations in its official cosmetics legislation overview. The Commission’s CPNP guidance explains the EU notification system. Notification is not a product approval or a certificate that replaces compliance checks.
The UK government publishes separate enforcement guidance for Great Britain and Northern Ireland. A GB-only responsible-person address should not be assumed sufficient for the Northern Ireland route.
Can the formula stay the same?
Possibly, but confirm this before committing to a common production batch. A qualified reviewer should screen the complete formulation against the current rules in each destination, including restrictions relevant to ingredient concentrations, intended use and product type. The two systems share historical foundations, but that is not proof that every current ingredient rule is identical.
Provide the reviewer with the controlled formula version, ingredient specifications, intended users, directions, exposure assumptions and proposed claims. Changing a fragrance, preservative, colour, concentration or intended use can affect the assessment. Even a seemingly minor supplier substitution should follow change control rather than being treated as an administrative update.
Claims also matter. Do not assume that a product marketed as a cosmetic in one territory has the same classification everywhere. Refer borderline or therapeutic claims for competent regulatory review. This article is a launch-planning guide, not a determination that a particular formulation or claim is lawful.
Can one packaging design work in both markets?
A common design may be possible when it includes all applicable information and remains legible. Review the finished artwork, not only the designer’s editable file. Check responsible-person information, ingredients, warnings, durability information, batch identification, product function, origin where required and relevant language obligations for each destination.
The current GB enforcement guidance includes a conditional transition for the Article 19(1)(a) address and origin requirements until 31 December 2027 where the stated EU-compliance condition is satisfied. This is not a blanket extension for all labelling requirements, and it does not remove other responsible-person duties. Verify eligibility before relying on it. See our UK cosmetic labelling guide for the separate GB and NI considerations.
| Shared element | What must be checked | Release decision |
|---|---|---|
| Formula | Current ingredient rules, use conditions, safety assessment and claims | Keep one formula only when both market reviews support it |
| Artwork | Addresses, origin, language, mandatory information and warnings | Use a common pack or controlled market-specific variants |
| Evidence package | Applicability of tests, specifications, assessment and document versions | Reuse suitable inputs; resolve gaps identified by each reviewer |
| Notification | Correct portal, responsible person and current product information | Complete each required route; do not substitute CPNP for SCPN |
| Commercial SKU | Traceability between formula, artwork, territory and batch | Choose a logistics structure that preserves release control |
Can the same documents support both launches?
Some technical inputs can support more than one market review. Examples include formula information, raw-material specifications, stability results, microbiological evidence and manufacturing records. Their usefulness depends on the actual product, assessment needs and the quality of the records. A document’s filename does not establish that it is adequate for both jurisdictions.
The responsible person must ensure the required product information is available and maintained. In GB, the government guidance describes an English-language Product Information File and retention for ten years after the last batch is placed on the market. The file includes more than a safety report: manufacturing information and relevant claim evidence also matter. Our UK Product Information File guide explains the dossier components.
Use a master document index with jurisdiction-specific records where necessary. Link each assessment, approved artwork and notification to the same controlled formula identifier. Ask the responsible persons and safety assessors to confirm whether existing evidence is suitable; do not promise that one report will always be accepted without further work.
How should a brand organise a dual-market release?
- Define destinations. List EU countries, GB and NI separately, including online sales and distributor territories.
- Freeze the product specification. Record the formula, packaging, intended use and claims to be reviewed.
- Confirm classification and ingredient compliance. Resolve market-specific gaps before ordering final printed packaging.
- Assign responsible persons. Confirm establishment, roles, document access and market coverage.
- Complete the evidence review. Address safety, manufacturing, testing and claim-support requirements.
- Approve market artwork and notifications. Make sure the reviewed product matches the information submitted.
- Release and monitor. Keep traceability, complaint handling and change control active after launch.
This is a recommended project sequence, not an official approval process or a guaranteed timetable. Launch time depends on the product, evidence gaps and the organisations involved. For the GB route, the government’s business guidance on making cosmetics available provides an official starting point.
What can a manufacturer provide, and what must the brand arrange?
| Workstream | Manufacturer support | Brand and appointed compliance parties |
|---|---|---|
| Technical inputs | Agreed formula, INCI information, specifications and available test records | Confirm that the inputs support each destination’s review |
| Packaging | Packaging specifications, compatibility information and controlled printing | Approve compliant artwork and market-specific instructions |
| Market access | Supply accurate manufacturing and product information | Arrange responsible-person coverage, assessments and notifications |
| Change control | Communicate agreed manufacturing or material changes | Assess effects on dossiers, labels, notifications and market release |
A manufacturing contract should clarify deliverables and responsibilities. The factory does not automatically become the responsible person simply because it produces the goods. Avoid purchasing an undefined “EU/UK certificate package” without identifying the underlying documents and accountable parties.
Common mistakes and a final go/no-go checklist
Typical mistakes include treating CPNP as UK-wide permission, overlooking NI, copying an EU label without a GB review, and using an old safety or artwork version after a formula change. A distributor’s request to expand sales into a new territory should trigger a compliance review, not only a revised shipping instruction.
- Every intended territory has an assigned compliance route.
- The current formula and claims have been reviewed for those territories.
- Responsible-person coverage and dossier access are confirmed.
- Final labels match the approved artwork versions.
- Required notifications refer to the actual product being supplied.
- Batch traceability and post-market responsibilities are documented.
If a material item remains unresolved, hold the affected market release. A product can be ready for one territory while still requiring work for another.
Frequently asked questions
Does selling the same formula mean I can use the same label?
No. Formula suitability and label compliance are separate reviews. A common label is possible only when its information satisfies the applicable requirements in every destination where it will be used.
Does a CPNP notification cover sales in Great Britain?
No. Great Britain uses SCPN. The EU and Northern Ireland routes should be assessed separately from GB, even when the underlying product is unchanged.
Can one Product Information File support both markets?
Shared technical records may support both, but the responsible persons must ensure the required information, access, language and jurisdiction-specific records are appropriate. Do not assume one dossier automatically meets every obligation.
Can the factory handle everything for the brand?
A manufacturer may offer agreed documentation or coordination services. The brand still needs clear contractual allocation of responsible-person, assessment, notification and release duties; manufacturing alone does not establish those roles.
Should I create different SKUs for EU and UK sales?
That is a commercial and traceability decision, not a universal legal rule. Separate SKUs can help control different labels or formulas; a shared SKU requires reliable identification of approved market configurations.
Plan the product before committing to packaging
MOOYAM provides cosmetic OEM/ODM manufacturing and technical documentation support for international beauty brands. Share your target territories, product specification and documentation needs early so manufacturing inputs and packaging changes can be coordinated with your appointed compliance professionals. Explore our OEM/ODM manufacturing support or contact MOOYAM to discuss the production scope.
Regulatory requirements may change. Brands should verify current requirements with the relevant regulatory authority or qualified compliance professional before placing cosmetic products on the market.